In this 90-day trial, 37 dogs were enrolled. Due to varying reasons, 32 of the dogs completed the full 90 days. Of those 32 dogs, 30 dogs demonstrated improved pain support. This was measured by an initial physical examination that included a pain and tenderness exam, mapping of the pain patterns, an informal gait analysis, a metabolic profile, and an interview with each dog’s owner. The same exams and mappings were performed during the biweekly assessments to inform dose adjustments while the metabolic parameters were repeated at the end of the study.

Throughout the study, each dog’s amount of CBD was closely monitored as the gabapentin was reduced. Additionally, of the 23 dogs in the study that were taking gabapentin (a prescription that helps with pain and seizures), 10 were able to discontinue use entirely and 11 others were able to decrease their dosage with the addition of our hemp-infused hemp seed oil. This ensured each dog’s quality of comfort was retained as their amounts were adjusted.

In order to remove any unnecessary variables, all participants continued to stay on all prescription medications to prevent a withdrawal pain response. This is applied to dogs on gabapentin, polysulfated glycosaminoglycan, and those receiving medical acupuncture. However, new prescriptions or medical modalities were not allowed during the course of this study. If a dog needed further care based on pre-existing conditions, they removed themselves from the study as needed.